Save the Cord Foundation recently interviewed Dr. Charles S. Cox, Jr. about his research using cord blood to potentially treat Traumatic Brain Injury (TBI).
According to Medscape, TBI is defined as, “a non-degenerative, non-congenital insult to the brain from an external mechanical force, possibly leading to a permanent or temporary impairment of cognitive, physical, and psychosocial functions, with an associated diminished or altered state of consciousness.”
Furthermore, traumaticbraininjury.com explains that TBI can limit the use of certain parts of the body and can alter personality. It can impair thinking, movement, sensation, emotional functioning, and more. In addition, no two-brain injuries are the same and the consequences of each individual brain injury may be extremely different.
According to Centers for Disease Control and Prevention, TBI contributes to about 30% of all injury deaths. Every day, 153 people in the United States die from injuries that include TBI.
In this short interview, Dr. Cox gives a brief overview of his work. He and his team recently completed their first acute, autologous cell therapy treatment Phase I study for traumatic brain injury in children aged 5-14. The study represents a significant milestone in Dr. Cox’s research focused on potentially treating traumatic brain injury with cord blood.
View the interview with Dr. Cox below or via our channel on YouTube.
Want to learn more about cord blood clinical trials?
1. Dawodu, ,A (2017) Traumatic Brain Injury (TBI) – Definition, Epidemiology, Pathophysiology. Medscape. Retrieved August 1, 2018, from https://emedicine.medscape.com/article/326510-overview
2. Mayo Foundation for Medical Education and Research, (2018) Traumatic Brain Injury. Mayo Clinic. Retrieved August 1, 2018, from http://www.mayoclinic.org/diseases-conditions/traumatic-brain-injury/symptoms-causes/syc-20378557
3. U.S. Department of Health & Human Services, (2017). TBI: Get the Facts. Centers for Disease Control and Prevention. Retrieved August 1, 2018, from https://www.cdc.gov/traumaticbraininjury/get_the_facts.html
Update: RECORDING NOW AVAILABLE. This presentation was made live on October 9th, 2017 during the AABB 2017 Annual Meetings. To view the recording, simply follow the link below.
Dr. Joanne Kurtzberg is recognized around the world for her outstanding work in cord blood research. In recent years, her research has been focused on using cord blood to potentially treat autism in young children. As the results from her clinical trials have started to come in, the medical world and parents have taken notice. She was recently interviewed by CNN along with her colleague, Dr. Geraldine Dawson, Director of Duke’s Center for Autism and Brain Development, about the encouraging results from these clinical trials. With more than two-thirds of children showing improvement, Dr. Kurtzberg and her team are now moving into phase two hoping to find a long-term treatment option for children with autism.
According to Dr. Kurtzberg, cord blood cells can work through paracrine and trophic mechanisms to help endogenous cells heal brain tissue damaged by disease or injury. Learning from observations made using unrelated donor umbilical cord blood transplant after myeloablative chemotherapy to treat children with certain inherited metabolic diseases, cord blood therapies have been developed to treat children with acquired brain injuries, like hypoxic ischemic encephalopathy, cerebral palsy, and autism.
As the research moves forward and new clinical trials begin, Dr. Kurtzberg has agreed to speak with our Share the Science community about the safety and feasibility of using autologous cord blood infusion in young children with autism spectrum disorder. She will also expand her talk into other areas of possible clinical application for cord blood therapies. Join us for this exclusive live event at the AABB Annual Meetings in San Diego, California.
Data from early phase human clinical trials for safety and efficacy in these diseases will be presented by Dr. Kurtzberg. Results of preclinical and IND-enabling studies will be presented to provide information about safety and potential mechanisms of action of cord blood cells in this setting.
In addition, attendees will learn about:
About the speaker
Joanne Kurtzberg, MD is the Director, Pediatric Blood and Marrow Transplant Program, Chief Scientific and Medical Officer, Robertson Clinical and Translational Cell Therapy Program, Director, Carolinas Cord Blood Bank and Co-Director, Stem Cell Laboratory.
She is an internationally renowned expert in pediatric hematology/oncology, pediatric blood and marrow transplant, umbilical cord blood banking and transplant, and novel applications of cord blood in the emerging fields of cellular therapies and regenerative medicine.
Over the last two decades, Dr. Kurtzberg has established an internationally known pediatric transplant program; one of the largest unrelated donor cord blood banks, the Carolinas Cord Blood Bank, in the world; and the Julian Robertson Cell and Translational Therapy Program (CT2) at Duke.
Dr. Kurtzberg has published more than 300 peer-reviewed papers, multiple chapters, and scientific reviews. She is a member of the American Society of Hematology, the American Association of Blood and Marrow Transplantation, the American Society of Pediatric Hematology/Oncology, the International Society of Cellular Therapies, the Pediatric Blood and Marrow Transplant Consortium (PBMTC), and other organizations. She serves on the Board of the Foundation of Accreditation of Cellular Therapies, Advisory Council of Blood Stem Cell Transplantation to Health and Human Services. Dr. Kurtzberg was awarded a Lifetime Achievement Award from the PBMTC in 2012.
We wish to thank Dr. Kurtzberg for sharing her
valuable insight on cord blood research for autism
with our Share the Science community.
We also wish to thank Mediware, Inc.
for their generous support making this webinar possible.
Previous Share the Science presentations have been archived for your reference. Discover the work of leading scientists and cord blood industry experts through this educational series. View the archive now.
Share the Science is made possible thanks to the generous support of Mediware, Inc.
Save the Cord Foundation is proud to be collaborating with the Cord Blood Association and 12 other leading industry groups to launch the first ever Cord Blood Connect conference this September in South Beach, Florida.
The cord blood industry has matured tremendously over the last decade. Yet, it is fair to say that it is still evolving simply because there is so much potential. Over the years, conferences held around the world have been crucial in pushing the industry forward as attendees often learn about new research or improving industry standards. However, it is rare to see a conference truly address all of the major aspects of the cord blood industry specifically. Cord Blood Connect promises to do just that!
Cord Blood Connect is an international conference that embraces all components of the cord blood community – public and private banking, clinical and laboratory investigations, manufacturing, administration, training and education.
Cord Blood Connect
The International Congress for Cord Blood
and Perinatal Tissue Research
September 14-16, 2018
Lowes Miami Beach Hotel
South Beach, Florida, USA
Hosted by the Cord Blood Association, attendees will be given the opportunity over the course of 3 days to explore multiple tracks for clinical and translational science and investigations, as well as education and training for cord blood bank administrative, technical and support personnel.
Cord blood experts from the 12 supporting organziations are leading numerous committees in an effort to identify speakers who will share their expertise and work with attendees during special training sessions. For example, the following committees have been developing the agenda:
Learn more on the Official Website for the conference.
REGISTRATION is now open with discounts for early registration and CBA members.
Write something about yourself. No need to be fancy, just an overview.